FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891966648> ?p ?o ?g. }

• W2891966648 endingPage "10" @default.
• W2891966648 startingPage "1" @default.
• W2891966648 abstract "Enterally administered riluzole is currently being investigated in a Phase II/III clinical trial for the treatment of acute spinal cord injury (SCI). Many SCI patients suffer from severe motor dysfunction and exhibit swallowing difficulties and cannot swallow riluzole tablets. The purpose of the present study was to develop a liquid solution formulation of riluzole, which can be administered more easily to this patient population with the capability to adjust the dose if needed. Riluzole was solubilized using water miscible organic solvents, namely, polyethylene glycol 400, propylene glycol and glycerin. A Central Composite Design (CCD) approach was used to develop an optimum co-solvent composition that can solubilize the entire 50 mg dose of riluzole in 5 ml. A three-factor five-level design was employed to investigate the effects of composition of co-solvents on riluzole solubility. The selected optimum formulation consists of 15% v/v PEG 400, 20% v/v propylene glycol and 10% v/v glycerin, with riluzole concentration of 10 mg/ml. The optimum composition was assessed for stability at different temperatures. Satisfactory stability was obtained at room temperature and 4 °C (t90 of 17 and 35 months, respectively). The optimum formulation of riluzole was suitable for both oral and intravenous administrations. Single dose pharmacokinetic studies of the optimum formulation by oral and IV routes were evaluated in rats, using commercially available Rilutek® tablets as a reference. The co-solvent formulation was well tolerated both orally and intravenously. In comparison to the commercial tablet, the co-solvent formulation had a faster rate of absorption and more sustained plasma levels with a significantly longer elimination half-life. Higher concentrations of riluzole in brain and spinal cord were achieved from co-solvent formulation as compared to tablet. The riluzole solution formulation is stable and offers advantages of ease of administration, consistent dosing, rapid onset and longer duration of action, better availability at site of action which can be extremely beneficial for the therapy in SCI patients." @default.
• W2891966648 created "2018-09-27" @default.
• W2891966648 creator A5013704257 @default.
• W2891966648 creator A5019647985 @default.
• W2891966648 creator A5033301762 @default.
• W2891966648 creator A5054255550 @default.
• W2891966648 date "2018-12-01" @default.
• W2891966648 modified "2023-10-16" @default.
• W2891966648 title "Rational design and development of a stable liquid formulation of riluzole and its pharmacokinetic evaluation after oral and IV administrations in rats" @default.
• W2891966648 cites W1869228284 @default.
• W2891966648 cites W1990803172 @default.
• W2891966648 cites W2014263842 @default.
• W2891966648 cites W2022264868 @default.
• W2891966648 cites W2031930233 @default.
• W2891966648 cites W2048409725 @default.
• W2891966648 cites W2064742557 @default.
• W2891966648 cites W2065010528 @default.
• W2891966648 cites W2071500473 @default.
• W2891966648 cites W2074713189 @default.
• W2891966648 cites W2085165928 @default.
• W2891966648 cites W2094013372 @default.
• W2891966648 cites W2099028265 @default.
• W2891966648 cites W2119831922 @default.
• W2891966648 cites W2144417922 @default.
• W2891966648 cites W2566911351 @default.
• W2891966648 cites W836150979 @default.
• W2891966648 doi "https://doi.org/10.1016/j.ejps.2018.09.004" @default.
• W2891966648 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30201516" @default.
• W2891966648 hasPublicationYear "2018" @default.
• W2891966648 type Work @default.
• W2891966648 sameAs 2891966648 @default.
• W2891966648 citedByCount "4" @default.
• W2891966648 countsByYear W28919666482019 @default.
• W2891966648 countsByYear W28919666482021 @default.
• W2891966648 crossrefType "journal-article" @default.
• W2891966648 hasAuthorship W2891966648A5013704257 @default.
• W2891966648 hasAuthorship W2891966648A5019647985 @default.
• W2891966648 hasAuthorship W2891966648A5033301762 @default.
• W2891966648 hasAuthorship W2891966648A5054255550 @default.
• W2891966648 hasConcept C112705442 @default.
• W2891966648 hasConcept C155574463 @default.
• W2891966648 hasConcept C170493617 @default.
• W2891966648 hasConcept C178790620 @default.
• W2891966648 hasConcept C185592680 @default.
• W2891966648 hasConcept C2776964284 @default.
• W2891966648 hasConcept C2779319286 @default.
• W2891966648 hasConcept C2780471494 @default.
• W2891966648 hasConcept C43617362 @default.
• W2891966648 hasConcept C55493867 @default.
• W2891966648 hasConcept C61174792 @default.
• W2891966648 hasConcept C71924100 @default.
• W2891966648 hasConcept C98274493 @default.
• W2891966648 hasConceptScore W2891966648C112705442 @default.
• W2891966648 hasConceptScore W2891966648C155574463 @default.
• W2891966648 hasConceptScore W2891966648C170493617 @default.
• W2891966648 hasConceptScore W2891966648C178790620 @default.
• W2891966648 hasConceptScore W2891966648C185592680 @default.
• W2891966648 hasConceptScore W2891966648C2776964284 @default.
• W2891966648 hasConceptScore W2891966648C2779319286 @default.
• W2891966648 hasConceptScore W2891966648C2780471494 @default.
• W2891966648 hasConceptScore W2891966648C43617362 @default.
• W2891966648 hasConceptScore W2891966648C55493867 @default.
• W2891966648 hasConceptScore W2891966648C61174792 @default.
• W2891966648 hasConceptScore W2891966648C71924100 @default.
• W2891966648 hasConceptScore W2891966648C98274493 @default.
• W2891966648 hasLocation W28919666481 @default.
• W2891966648 hasLocation W28919666482 @default.
• W2891966648 hasOpenAccess W2891966648 @default.
• W2891966648 hasPrimaryLocation W28919666481 @default.
• W2891966648 hasRelatedWork W1819159769 @default.
• W2891966648 hasRelatedWork W1912440894 @default.
• W2891966648 hasRelatedWork W2056283610 @default.
• W2891966648 hasRelatedWork W2083917552 @default.
• W2891966648 hasRelatedWork W2748952813 @default.
• W2891966648 hasRelatedWork W2833632634 @default.
• W2891966648 hasRelatedWork W2899084033 @default.
• W2891966648 hasRelatedWork W3180597368 @default.
• W2891966648 hasRelatedWork W49339365 @default.
• W2891966648 hasRelatedWork W980056702 @default.
• W2891966648 hasVolume "125" @default.
• W2891966648 isParatext "false" @default.
• W2891966648 isRetracted "false" @default.
• W2891966648 magId "2891966648" @default.
• W2891966648 workType "article" @default.